The renin-angiotensin system and the developing retinal vasculature

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 3, 2005, Pages 1069-1077

  Sarlos, Stella ^a   Wilkinson Berka, Jennifer L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; PRORENIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; REN2 PROTEIN, MOUSE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; RETINA DEVELOPMENT; RETINA GANGLION CELL; TRANSGENIC ANIMAL; VASCULARIZATION; ANGIOGENESIS; ANIMAL; DRUG EFFECT; ENZYME IMMUNOASSAY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; AUTORADIOGRAPHY; IMMUNOENZYME TECHNIQUES; LISINOPRIL; LOSARTAN; NEOVASCULARIZATION, PHYSIOLOGIC; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN; RENIN-ANGIOTENSIN SYSTEM; RETINAL GANGLION CELLS; RETINAL VESSELS;

EID: 16244376186     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0885     Document Type: Article

References (62)

1. de Gooyer TE, Skinner SL, Wlodek ME, Kelly DJ, Wilkinson-Berka JL. Angiotensin II influences ovarian follicle development in the transgenic (mRen-2)27 and Sprague-Dawley rat. J Endocrinol. 2004;180:311-324.
2. Nemeth G, Pepperell JR, Yamada Y, Palumbo A, Naftolin F. The basis and evidence of a role for the ovarian renin-angiotensin system in health and disease. J Soc Gynecol Invest. 1994;1:118-127.
3. Rong P, Wilkinson-Berka JL, Skinner SL. Control of renin secretion from adrenal gland in transgenic Ren-2 and normal rats. Mol Cell Endocrinol. 2001;173:203-212.
4. Mulrow PJ, Franco-Saenz R. The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. J Hypertens. 1996;14:173-176.
5. Wilkinson-Berka JL, Kelly DJ, Rong P, Campbell DJ, Skinner SL. Characterisation of a thymic renin-angiotensin system in the transgenic m(Ren-2)27 rat. Mol Cell Endocrinol. 2002;194:201-209.
6. Berka JL, Stubbs AJ, Wang DZ-M, et al. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci. 1995;36:1450-1458.
7. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF and angiopoietin. Am J Pathol. 2003:879-887.
8. Wagner J, Danser AHJ, Derkx FHM, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996;80:159-163.
9. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci. 1999;11:3387-3394.
10. Kohler K W-ST, Jurlikes B, Guenther E, Zrenner E. Angiotensin II in the rabbit retina. Vis Neurosci. 1997;14:63-71.
11. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994;35:1008-1018.
12. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res. 1998;82:619-628.
13. 2 receptors. Kidney Int. 1998;54:S95-S99.
14. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia. 2001;44:883-888.
15. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol. 2001;280:C1358-C1366.
16. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002;82:747-756.
17. Cao Z, Kelly DJ, Cox A, et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000;58:2437-2451.
18. Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest. 1996;98:418-425.
19. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest. 1991;88:921-933.
20. Meyer BR, Vashishtha A. Angiotensin-converting-enzyme genotype and ischemic heart disease. N Engl J Med. 1995;333:458-459; author reply 459-60.
21. Rockwood EJ, Fantes F, Davis EB, Anderson DR. The response of retinal vasculature to angiotensin. Invest Ophthalmol Vis Sci. 1987;28:676-682.
22. Constad WH, Fiore P, Samson C, Cinotti AA. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol. 1988;105:674-677.
23. Datum KH, Zrenner E. Angiotensin-like immunoreactive cells in the chicken retina. Exp Eye Res. 1991;53:157-165.
24. Jurklies B, Eckstein A, Jacobi P, Kohler K, Risler T, Zrenner E. The renin-angiotensin system: a possible neuromodulator in the human retina? Ger J Ophthalmol. 1995;4:144-150.
25. Jacobi PC, Osswald H, Jurklies B, Zrenner E. Neuromodulatory effects of the renin-angiotensin system on the cat electroretinogram. Invest Ophthalmol Vis Sci. 1994;35:973-980.
26. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia. 2003;46:401-408.
27. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985;105:141-145.
28. Le Noble FA, Hekking JW, Van Straaten HW, Slaaf DW, Struyker Boudier HA. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol. 1991; 195:305-306.
29. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98:671-679.
30. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67-75.
31. Moravski CJ, Skinner SL, Stubbs AJ, et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol. 2003;162:151-160.
32. Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000;36:1099-1104.
33. Lonchampt M, Pennel L, Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest Ophthalmol Vis Sci. 2001;42:429-432.
34. Tadesse M, Yan Y, Yossuck P, Higgins RD. Captopril improves retinal neovascularization via endothelin-1. Invest Ophthalmol Vis Sci. 2001;42:1867-1872.
35. Provis JM, Leech J, Diaz CM, Penfold PL, Stone J, Keshet E. Development of the human retinal vasculature: cellular relations and VEGF expression. Exp Eye Res. 1997;65:555-568.
36. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
37. Chan-Ling T, McLeod DS, Hughes S, et al. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci. 2004;45:2020-2032.
38. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990;344: 541-544.
39. Fabiani ME, Hawkes DJ, Frauman AG, Tikellis C, Johnston CI, Wilkinson-Berka JL. Regulation of angiotensin II receptors in the prostate of the transgenic (mRen-2)27 rat: effect of angiotensin-converting enzyme inhibition. Int J Biochem Cell Biol. 2003;35: 973-983.
40. Sernia C, Davis M, Thomas WG. Purification of rat angiotensinogen. Prep Biochem. 1986;16:45-59.
41. Mendelsohn FAO, Milan MA, Quirion R, Aguilera G, Chou S, Catt KJ. Localisation of angiotensin II receptors in rat and monkey kidney by in vitro autoradiography. Kidney Int. 1987;31(suppl 20):S40-S44.
42. Browning J, Wylie CK, Gole G. Quantification of oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1997;38: 1168-1174.
43. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:697-707.
44. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia. 2000;43:1360-1367.
45. Higgins RD, Yan Y, Geng Y, Sharma J, Barr SM. Captopril and vascular endothelial growth factor in a mouse model of retinopathy. Curr Eye Res. 2003;27:123-129.
46. Morrell NW, Grieshaber SS, Danilov SM, Majack RA, Stenmark KR. Developmental regulation of angiotensin converting enzyme and angiotensin type 1 receptor in the rat pulmonary circulation. Am J Respir Cell Mol Biol. 1996;14:526-537.
47. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int. 1999;56:211-221.
48. Yosipiv IV, Dipp S, el-Dahr SS. Ontogeny of somatic angiotensin- converting enzyme. Hypertension. 1994;23:369-374.
49. Forhead AJ, Gulati V, Poore KR, Fowden AL. Ontogeny of pulmonary and renal angiotensin-converting enzyme in pigs. Mol Cell Endocrinol. 2001;185:127-133.
50. Pitt BR, Lister G, Davies P, Reid L. Correlation of pulmonary ACE activity and capillary surface area during postnatal development. J Appl Physiol. 1987;62:2031-2041.
51. Wong RO, Hughes A. The morphology, number, and distribution of a large population of confirmed displaced amacrine cells in the adult cat retina. J Comp Neurol. 1987;255:159-177.
52. Tout S, Chan-Ling T, Hollander H, Stone J. The role of Muller cells in the formation of the blood-retinal barrier. Neuroscience. 1993; 55:291-301.
53. Nork T, Wallow I, Sramek S, Anderson G. Muller cells involvement in proliferative diabetic retinopathy. Arch Ophthalmol. 1987;105: 1424-1429.
54. Wilkinson-Berka JL, Fletcher EL. Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy. Curr Pharm Des. 2004;10:3313-3330.
55. Nunes-Mamede ML, De Mello FG, Martins AR. Effect of p-mercuribenzoate on the subestimation of angiotensin-converting enzyme measurement during chick retina development. J Neurosci Methods. 1990;31:7-11.
56. Wheeler-Schilling TH, Sautter M, Guenther E, Kohler K. Expression of angiotensin-converting enzyme (ACE) in the developing chicken retina. Exp Eye Res. 2001;72:173-182.
57. Kelly DJ, Wilkinson-Berka JL, Allen TA, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int. 1998; 54:343-352.
58. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int. 2000; 57:1882-1894.
59. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene. 2003;22:6537-6548.
60. Mifsud SA, Skinner SL, Cooper ME, Kelly DJ, Wilkinson-Berka JL. Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. J Am Soc Nephrol. 2002;13:684-692.
61. Wilkinson-Berka JL, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ. Renoprotective and antihypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant. 2001;16: 1343-1349.
62. Cao Z, Dean R, Wu L, Casley D, Cooper ME. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension. 1999;34:408-414.